Molecular epidemiology and nitrofurantoin resistance determinants of nitrofurantoin-non-susceptible Escherichia coli isolated from urinary tract infections by Mottaghizadeh, F. et al.
Journal of Global Antimicrobial Resistance 21 (2020) 335–339Molecular epidemiology and nitrofurantoin resistance determinants of
nitrofurantoin-non-susceptible Escherichia coli isolated from urinary
tract infections
Fatemeh Mottaghizadeha, Hanieh Mohajjel Shojaa,*, Mehri Haeilia,*,
Davood Darban-Sarokhalilb
aDepartment of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran
bDepartment of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
A R T I C L E I N F O
Article history:
Received 13 September 2019
Received in revised form 30 September 2019
Accepted 3 October 2019








A B S T R A C T
Objectives: The worldwide emergence of multidrug-resistant uropathogens has resulted in the revival of
old antibiotics such as nitrofurantoin (NIT) for the treatment of uncomplicated urinary tract infections
(UTIs). This study aimed to identify determinants of NIT resistance and to investigate the genetic diversity
of NIT-resistant (NIT-R) Escherichia coli isolates.
Methods: Six NIT-R and three NIT-susceptible clinical E. coli isolates from patients with UTI were studied.
The susceptibility of the isolates to various classes of antibiotics was evaluated by disk diffusion. The
presence of plasmid-encoded efflux pump genes (oqxA and oqxB) was investigated by PCR. Nucleotide
sequences of the nfsA, nfsB and ribE genes were determined. The genetic relatedness of the NIT-R isolates
was evaluated by multilocus sequence typing (MLST).
Results: All six NIT-R isolates were characterised with high-level NIT resistance (MIC  512 mg/L) and they
belonged to five distinct STs including ST131 (n = 2), ST73, ST405, ST10 and ST354 (n = 1 each). Amikacin,
carbapenems, minocycline, tigecycline and fosfomycin were the most active agents against the studied
uropathogens. The oqxA and oqxB genes were not detected in any isolate. All NIT-R isolates harboured
inactivating genetic alterations in nfsA and nfsB [NfsA H11Y, S33N, S38Y, W212R substitutions, Dg638
(frameshift), Da64-g73 (frameshift) and NfsB F84S, P45S, W94Stop, E197Stop substitutions, DnfsB locus].
The ribE gene of most isolates was unaffected, except for one isolate co-harbouring a deleterious RibE
G85C substitution and NfsA/B alterations.
Conclusion: NIT resistance in the studied E. coli isolates was mainly mediated by nfsA and nfsB alterations.
© 2019 Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Escherichia coli is the most common uropathogenic bacterium
causing community-acquired urinary tract infections (UTIs) [1,2].
The recent emergence and spread of multidrug-resistant E. coli
isolates has led to renewed interests in older ‘forgotten’ antibiotics
such as nitrofurantoin (NIT) for the management of uncomplicated
UTIs.NIT is a synthetic bactericidal agent that is rapidly absorbed
and is excreted in the urine to generate high therapeutic
concentrations following oral administration [3]. It has a broad
antibacterial spectrum and is particularly effective against the* Corresponding authors.
E-mail addresses: mohajelh@yahoo.com (H. Mohajjel Shoja),
m.haeili@tabrizu.ac.ir, m.haeili@yahoo.com (M. Haeili).
http://dx.doi.org/10.1016/j.jgar.2019.10.002
2213-7165/© 2019 Published by Elsevier Ltd on behalf of International Society for Antimi
(http://creativecommons.org/licenses/by-nc-nd/4.0/).principal Gram-negative and Gram-positive uropathogens [3]. It
became a preferred drug in the international consensus guidelines
for UTI in 2010 and has been successfully used for a long time for
the management of lower UTIs in adults, children and pregnant
women [4]. Despite being in clinical use for decades, the exact
mode of action of NIT is not completely understood, although it
appears to involve the formation of reduced reactive intermediates
that disrupt or alter bacterial ribosomal proteins and other
macromolecules, halting vital bacterial biochemical processes
[5]. The formation of these toxic intermediates is mediated by
bacterial nitroreductases encoded by nfsB and nfsA genes [6].
Overall, clinical resistance to NIT remains low among E. coli isolates
(<10%) and many multidrug-resistant organisms retain suscepti-
bility to this agent [7,8]. To date, limited studies are available
unravelling the mechanisms of NITresistance among uropathogens.
NIT resistance in E. coli is found to be mainly attributed to geneticcrobial Chemotherapy. This is an open access article under the CC BY-NC-ND license
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encoding lumazine synthase, an essential enzyme involved in
biosynthesis of the flavin mononucleotide, which is an important
cofactor for NfsA and NfsB [10]. Furthermore, the plasmid-encoded
efflux pump OqxAB has been found to mediate NIT resistance in E.
coli isolates from human and animal sources [11].
Whilst the incidence of NIT-resistant (NIT-R) uropathogenic E.
coli isolates is negligible among Iranian patients, little is known
about the mechanisms mediating NIT resistance among E. coli from
this geographic region. Therefore, the current study aimed to
identify the determinants of NIT resistance and to investigate the
genetic diversity of NIT-R E. coli isolates.
2. Materials and methods
2.1. Bacterial isolates and antimicrobial susceptibility testing
Six NIT-R and three NIT-susceptible (NIT-S) clinical E. coli isolates
from patients with UTI were studied. Identification of the isolates to
species level was performed byconventional biochemical tests [12].
The susceptibility of all of the isolates to various classes of
antibiotics was determined by the Kirby–Bauer disk diffusion
method according to Clinical and Laboratory Standards Institute
(CLSI) guidelines [13] using the following antibiotics: nalidixic
acid (30 mg); ciprofloxacin (5 mg); levofloxacin (5 mg); gatifloxacin
(5 mg); moxifloxacin (5 mg); gentamicin (10 mg); amikacin (30 mg);
chloramphenicol (30 mg); ampicillin (10 mg); ceftriaxone (30
mg); cefepime (30 mg); ceftazidime (30 mg); imipenem (10 mg);
meropenem (10 mg); doxycycline (30 mg); minocycline (30 mg);
trimethoprim/sulfamethoxazole (SXT) (23.75/1.25 mg); fosfomycin
(200 mg) (BBLTM Sensi-DiscTM; Becton Dickinson, Sparks, MD, USA);
and tigecycline (15 mg) (Mast Co., Bootle, UK). US Food and Drug
Administration (FDA) interpretative criteriawere used todetermine
tigecycline susceptibility by the disk diffusion method (susceptible,
19 mm; intermediate, 15–18 mm; resistant, 14 mm). All isolates
were tested for extended-spectrum β-lactamase (ESBL) production
using a phenotypic confirmatory test (the combined disk method)
according to CLSI guidelines. Minimum inhibitory concentrations
(MICs) of NIT were determined using Liofilchem1 MIC Test Strips
(Liofilchem, Roseto degli Abruzzi, Italy) containing a concentration
gradient range of NIT (0.032–512 mg/L) and were interpreted
according to CLSI guidelines as follows: susceptible, 32 mg/L;
intermediate, 64 mg/L; and resistant, 128 mg/L [13]. NIT-S E. coli
ATCC 25922 reference strain was used as quality control strain for
antimicrobial susceptibility testing.Table 1
Nucleotide sequences of primers used in this study.



















Ta, annealing temperature.2.2. Identification of molecular determinants of nitrofurantoin
resistance
To explore the molecular determinants mediating NIT resis-
tance in the studied isolates, chromosomal DNA was extracted
from all of the NIT-R and NIT-S isolates by the boiling method
(https://www.eurl-ar.eu/CustomerData/Files/Folders/21-proto-
cols/278_mcr-multiplex-pcr-protocol-v2-oct16.pdf). PCR amplifi-
cation of genes encoding the oxygen-insensitive NAD(P)H
nitroreductases NfsA and NfsB as well as lumazine synthase RibE
was performed using primers targeting amplification of coding
sequences as well as some flanking regions (external primers). For
isolates for which no amplification product was obtained using the
external primers, internal primers targeting amplification of an
internal region of the studied genes were used (Table 1). In
addition, presence of the plasmid-encoded efflux pump OqxAB
was examined by PCR method using the primers listed in Table 1.
PCR products were sequenced and the nucleotide and deduced
protein sequences were analysed at the National Center for
Biotechnology Information (NCBI) website. The impact of identi-
fied amino acid substitutions on the biological function of the
protein (i.e. neutral or deleterious) was further predicted using the
Protein Variation Effect Analyzer (PROVEAN) software tool (http://
provean.jcvi.org/index.php) [15].
2.3. Genotyping by multilocus sequence typing (MLST)
All NIT-R isolates were subjected to MLST as described previously
[16]. PCR amplification and sequencing of internal fragments of seven
housekeeping genes (adk, fumC, gyrB, icd, mdh, purA and recA) were
performed and alleles and sequence types (STs) were assigned in
accordance with the E. coli MLST database website (http://enter-
obase.warwick.ac.uk/species/ecoli/allele_st_search). All of the




3.1. Bacterial genotyping and antimicrobial susceptibility testing
All six NIT-R isolates were characterised by high-level NIT
resistance (MIC  512 mg/L) and they belonged to five distinct STs,
including ST131 (n = 2 isolates), ST73, ST405, ST10 and ST354 (n = 1
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urinary E. coli isolates were susceptible to tigecycline, carbape-
nems (imipenem, meropenem) and amikacin and 8 (88.9%) were
susceptible to fosfomycin. Whilst 83.3% (5/6) of the NIT-R isolates
were also resistant to all quinolones (nalidixic acid, ciprofloxacin,
levofloxacin, gatifloxacin, moxifloxacin), only 33.3% (1/3) of NIT-S
isolates showed resistance to this family of antibiotics.
Rates of resistance to other antibiotics among the NIT-R and
NIT-S isolates, respectively, were: gentamicin, 33.3% and 0%; SXT,
83.3% and 33.3%; chloramphenicol, 16.7% and 0%; ampicillin, 100%
and 66.7%; ceftriaxone, 83.3% and 66.7%; cefepime, 33.3% and
66.7%; ceftazidime, 50.0% and 33.3%; minocycline, 0% and 0%; and
doxycycline, 33.3% and 33.3% (Table 2). Also, 66.7% of NIT-R isolates
(4/6) and NIT-S (2/3) were found to produce an ESBL (strains EC11,
EC15, EC109, EC138, EC167 and EC168).
3.2. Mechanisms of nitrofurantoin resistance
To determine the molecular mechanisms conferring NIT
resistance in the studied isolates, the presence of plasmid-encoded
oqxA and oqxB genes was investigated by PCR and the nucleotideTable 2
Characteristics of nitrofurantoin-resistant (NIT-R) and nitrofurantoin-susceptible (NIT-S
Isolate NIT MIC
(mg/L)
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V93A WT ND GEN, AMK, IPM, MEM
TGC, CHL
NIT, nitrofurantoin; MIC, minimum inhibitory concentration; MLST, multilocus seque
determined; GEN, gentamicin; AMK, amikacin; CHL, chloramphenicol; IPM, imipene
sulfamethoxazole; FOS, fosfomycin; DOX, doxycycline; CRO, ceftriaxone; FEP, cefepim
levofloxacin; GAT, gatifloxacin; MFX, moxifloxacin.
a nfsB locus not amplifiable with all primers used in this study.sequences of chromosomally encoded genes including nfsA, nfsB
and ribE were determined. The plasmid-encoded genes oqxA and
oqxB were not detected in any isolate, indicating that mechanisms
other than antibiotic extrusion by this pump are mediating
resistance in the studied isolates. Analysis of nfsA and nfsB gene
sequences in the NIT-R isolates revealed several deleterious
genetic alterations (Table 2). Whilst all NIT-R isolates harboured
deleterious genetic alterations both in nfsA and nfsB, only one
isolate harboured ribE alterations.
Analysis of the nfsB gene in two NIT-R isolates assigning to ST73
and ST405 revealed no amplification product using all three pairs
of external primers targeting amplification of the nfsB coding
sequence as well as some flanking regions, suggesting deletion of
the nfsB locus. Absence of the nfsB locus in the genome of these
isolates was confirmed by PCR using the nfsB internal primers. The
NfsB protein was inactivated by premature termination due to
nonsense mutations at codons 94 (W94stop, TGG < TGA) and 197
(E197Stop, GAA < TAA) in two NIT-R isolates assigned to ST10 and
ST354. These alterations resulted in the production of a truncated
and most likely non-functional 93- and 196-amino acid long
protein, respectively, instead of a wild-type protein of 217 amino) Escherichia coli isolated from urinary tract infections.
I R
, MEM, MNO, TGC, SXT, FOS DOX CRO, FEP, AMP, CAZ, NAL, CIP, LVX,
GAT, MFX
, MEM, DOX, MNO, TGC, NAL, CIP,
FOS
FEP CRO, AMP, SXT
, FOS, TGC MNO,
CHL
CRO, FEP, AMP, CAZ, NAL, CIP, LVX,
GAT, MFX, DOX, SXT
O, TGC, FEP, CRO, CAZ, FOS None NAL, CIP, LVX, GAT, MFX, CHL, AMP,
SXT, DOX, GEN
X, MNO, TGC, FEP, CHL None CRO, AMP, CAZ, NAL, CIP, LVX, GAT,
MFX, GEN, FOS, SXT
, MNO, TGC, CAZ, FEP, CHL, FOS DOX CRO, AMP, NAL, CIP, LVX, GAT, MFX,
SXT





, DOX, MNO, TGC, FOS CHL,
AMP
CRO, FEP, CAZ, NAL, CIP, LVX, GAT,
MFX, SXT
, CIP, LVX, GAT, MFX, FOS, SXT, CAZ, MNO CRO, FEP, AMP, DOX, NAL
nce typing; S, susceptible; I, intermediate; R, resistant; WT, wild-type; ND, not
m; MEM, meropenem; MNO, minocycline; TGC, tigecycline; SXT, trimethoprim/
e; AMP, ampicillin; CAZ, ceftazidime; NAL, nalidixic acid; CIP, ciprofloxacin; LVX,
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nfsA deletions including guanine deletion at position +638 and a
10-nucleotide deletion (+64 to +73) were observed, which resulted
in frameshifting in both cases and the introduction of several stop
codons in the coding region of protein in the latter case. PROVEAN
prediction of the amino acid changes showed that NfsA S38Y (TCC
< TAC), W212R (TGG < AGG), S33 N (AGC < AAC) and H11Y (CAT <
TAT) and NfsB F84S (TTC < TCC) and P45S (CCG < TCG) as well as
RibE G85C (GGT < TGT) substitutions could have an inactivating
impact on the function of the corresponding proteins (Table 3).
However, other amino acid substitutions observed in NIT-R isolates
as well as all substitutions identified in NIT-S isolates were
categorised as neutral changes that are not likely to be involved in
NIT resistance development in the studied isolates.
3.3. Nucleotide sequence accession nos
The nucleotide sequences of the mutated nfsA, nfsB and ribE
genes have been deposited in the GenBank nucleotide sequence
database under accession nos. MN256119–MN256126, MN215887,
MN381176, and MN273513–MN273519.
4. Discussion and conclusions
Despite being in clinical use for decades, NIT has retained its
activity against multidrug-resistant urinary E. coli isolates and the
incidence of resistance to this old antibiotic has remained
relatively low [17]. In the current study, MLST results revealed
that the six NIT-R E. coli isolates were clonally diverse and were
distributed into five distinct STs, with ST131 being the most
frequent genotype (33.3%; n = 2 isolates) and the other STs being
found in single isolates each (16.7%; n = 1). Escherichia coli ST131
has been found to contribute significantly to the spread of
multidrug resistance in the community and often encodes multiple
virulence products associated with mobile genetic elements and is
responsible for a high proportion of urinary tract and bloodstream
infections [18,19]. According to antimicrobial susceptibility testing
results, amikacin, minocycline, tigecycline, carbapenems and
fosfomycin were the most active agents against the studiedTable 3
Predicting the impact of amino acid substitutions on the biological function of NfsA,
NfsB and RibE proteins using PROVEAN tool.
Protein Variant PROVEAN score Predictiona Isolatesb
NfsA H11Y –5.746 Deleterious NIT-R
S33N –2.711 Deleterious NIT-R
S38Y 5.617 Deleterious NIT-R
E58D 1.866 Neutral NIT-R, NIT-S
Q72K –0.940 Neutral NIT-R
I117T 0.634 Neutral NIT-R, NIT-S
K141E 1.207 Neutral NIT-R, NIT-S
Q147R –1.170 Neutral NIT-R
A172S 0.252 Neutral NIT-S
G187D 1.554 Neutral NIT-R, NIT-S
A188V 0.338 Neutral NIT-R
A188E 0.694 Neutral NIT-R
W212R –12.644 Deleterious NIT-R
NfsB P45S –7.680 Deleterious NIT-R
G66D –1.775 Neutral NIT-R, NIT-S
F84S –5.862 Deleterious NIT-R
V93A 2.155 Neutral NIT-R, NIT-S
K130R –0.516 Neutral NIT-S
I171F –2.306 Neutral NIT-S
A174E 1.621 Neutral NIT-R, NIT-S
Q210H –1.878 Neutral NIT-S
RibE G85C –8.850 Deleterious NIT-R
NIT-R, nitrofurantoin-resistant; NIT-S, nitrofurantoin-susceptible.
a PROVEAN score cut-off = –2.5.
b Isolates in which the specific amino acid substitution has been identified.uropathogens, which showed either a minor or no resistance rate.
Analysis of NfsA, NfsB and RibE of NIT-R and NIT-S clinical E. coli
strains demonstrated several amino acid substitutions. However,
none of the substitutions identified in NIT-S isolates were found to
have major implications for the functionality of the studied
enzymes as predicted by PROVEAN tool and were categorised as
neutral changes. Among the identified NfsA substitutions S38Y,
W212R, S33N, H11Y, A188V, A188E, Q72K, Q147R, A172S, I117T,
G187D, K141E and E58D, only the first four mutations, and among
the NfsB substitutions P45S, F84S, K130R, I171F, G66D, V93A,
A174E and Q210H only the first two mutations were predicted by
the PROVEAN tool to have a deleterious impact on protein structure
and were only harboured by the NIT-R isolates. We suggest that
NfsA I117T, G187D, K141E and E58D and NfsB G66D, V93A and
A174E substitutions cannot contribute to NIT resistance alone since
these mutations also were found in NIT-S isolates and surprisingly
the PROVEAN tool predicted these alterations as neutral changes.
The NfsB nonsense mutations (W94stop, E197stop) in two NIT-R
isolates resulted in the production of a truncated and most likely
non-functional NfsB protein compared with the 217-amino acid
wild-type protein and might explain the origin of NIT resistance in
these isolates. The W94stop mutation has been also reported by
Sandegren et al. among NIT-R isolates [20], reinforcing the
hypothesis that position +282 in nfsB (codon 94) is a critical
region that is prone to mutate upon resistance emergence.
Production of truncated/inactivated NfsB or its absence in some
NIT-R isolates might have resulted in the inability/reduced ability
of NIT-R isolates to cause nitroreduction of NIT and the production
of active intermediates from the compound. The lumazine
synthase RibE of most of the studied isolates remained unaffected,
except for one NIT-R isolate showing a G85C substitution that was
predicted to have negative impact on protein structure. However,
since this isolate also co-harboured a mutated NfsA and NfsB, the
exact role of RibE mutation in resistance emergence in this isolate
remains unknown. Studies demonstrating the role of RibE
substitutions in the development of NIT resistance are scarce. It
was initially described by Vervoort et al. who reported a
laboratory-induced NIT-R E. coli isolate lacking NfsA/NfsB alter-
ations but harbouring a 12-nucleotide deletion in the ribE gene
[10]. However, they reported six NIT-R clinical E. coli isolates that
lacked any RibE alterations [10]. Moreover, Ho et al. could not find
any significant ribE mutations in NIT-R E. coli isolates originating
from patients with UTI and from food-producing animals [11]. The
oqxAB genes were not detected in any isolate in the current study,
indicating that this efflux pump is not mediating NIT resistance in
the studied isolates. Ho et al. studied the contribution of OqxAB to
NIT resistance in E. coli from human and animal sources and
reported a high prevalence of oqxAB among NIT-non-susceptible
isolates (NIT-intermediate 11.5–45.5% and NIT-resistant 39.2–
65.5%) [11]. In a study from China performed on 18 NIT-R clinical
E. coli isolates, I117 T and G187D in NfsA as well as V93A, M57I and
K122R in NfsB were the most common substitutions identified in
the studied proteins and were predicted to have a neutral impact
on protein structure [21]. In approximately 44% of resistant and
11% of intermediate isolates, but not in NIT-S isolates, the oqxA and
oqxB genes were detected, which were found to contribute to
elevated NIT MICs in isolates harbouring mutated nfsA and nfsB
[21]. It has been demonstrated that nfsA alterations cause only low-
level resistance and that the development of high-level resistance
(MIC of 128 mg/L) occurs when inactivation of nfsB combines with
nfsA inactivation [6,20]. These data showed that all NIT-R isolates
were characterised by high-level NIT resistance (MIC  512 mg/L)
and that NfsA and NfsB activities were probably knocked-out in all
isolates.
In conclusion, NIT resistance in the studied isolates was mainly
mediated by nfsA and nfsB alterations that were found in clonally
F. Mottaghizadeh et al. / Journal of Global Antimicrobial Resistance 21 (2020) 335–339 339diverse uropathogens. The high rate of resistance to quinolones
observed in this study is an alarming issue for infection control
programmes, necessitating restriction of empirical prescription of
critically important antibiotics such as fluoroquinolones to the
most severe infections as well as their application according to
antimicrobial susceptibility testing results.
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